Ultragenyx Pharmaceutical Ownership | Who Owns Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical Ownership Summary
Ultragenyx Pharmaceutical is owned by 57.67% institutional investors, 3.13% insiders, and 39.20% retail investors. Vanguard group is the largest institutional shareholder, holding 10.29% of RARE shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.04% of its assets in Ultragenyx Pharmaceutical shares.
RARE Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Ultragenyx Pharmaceutical | 57.67% | 3.13% | 39.20% |
| Sector | Healthcare Stocks | 232.01% | 10.74% | -142.75% |
| Industry | Biotech Stocks | 381.47% | 10.55% | -292.02% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vanguard group | 10.26M | 10.29% | $236.07M |
| Fmr | 7.28M | 7.40% | $219.08M |
| Blackrock | 5.60M | 6.65% | $230.30M |
| Blackrock funding, inc. /de | 6.63M | 6.65% | $152.53M |
| Jpmorgan chase | 3.97M | 3.98% | $91.40M |
| Sands capital management | 3.77M | 3.83% | $113.40M |
| State street | 3.69M | 3.75% | $111.07M |
| Rtw investments, lp | 3.26M | 3.31% | $98.01M |
| Baker bros. advisors lp | 2.77M | 2.82% | $83.40M |
| Price t rowe associates inc /md/ | 2.31M | 2.35% | $69.49M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Cutter capital management, lp | 406.80K | 7.01% | $17.11M |
| B group | 135.00K | 2.99% | $4.06M |
| Sphera funds management | 352.56K | 2.24% | $10.60M |
| Rock springs capital management lp | 1.25M | 2.19% | $37.49M |
| Palo alto investors lp | 369.53K | 2.06% | $11.12M |
| Bioimpact capital | 395.70K | 1.95% | $11.90M |
| Catalio capital management, lp | 291.26K | 1.62% | $8.76M |
| Suvretta capital management | 2.02M | 1.55% | $60.73M |
| Privium fund management b.v. | 357.50K | 1.51% | $8.22M |
| Rtw investments, lp | 3.26M | 1.21% | $98.01M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Fmr | 7.28M | 0.01% | 4.68M |
| Rtw investments, lp | 3.26M | 1.21% | 1.55M |
| Norges bank | 1.26M | 0.00% | 1.26M |
| State street | 3.69M | 0.00% | 1.12M |
| Morgan stanley | 1.83M | 0.00% | 916.11K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Alkeon capital management | - | - | -1.69M |
| Deep track capital, lp | - | - | -1.35M |
| Alliancebernstein | 26.71K | 0.00% | -1.23M |
| Adage capital partners gp | 430.00K | 0.02% | -1.10M |
| Frazier life sciences management | - | - | -983.72K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Norges bank | 1.26M | 0.00% | 1.26M | $29.00M |
| Braidwell lp | 588.70K | 0.53% | 588.70K | $17.71M |
| Voloridge investment management | 482.58K | 0.05% | 482.58K | $14.52M |
| Jefferies financial group | 477.09K | 0.06% | 477.09K | $10.97M |
| Axa investment managers | 417.20K | 0.03% | 417.20K | $12.55M |
Sold Out
| Holder | Change |
|---|---|
| Stephens consulting | -1.00 |
| Twin peaks wealth advisors | -3.00 |
| Concourse financial group securities | -3.00 |
| Wealthspire advisors | -4.00 |
| True wealth design | -5.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 197 | -40.66% | 57,538,166 | -39.74% | 57 | 0.61% | 105 | -42.62% | 60 | -36.84% |
| Sep 30, 2025 | 316 | -7.87% | 91,125,125 | -3.19% | 92 | 1.01% | 174 | -2.79% | 92 | -9.80% |
| Jun 30, 2025 | 338 | 6.29% | 94,259,190 | 8.19% | 95 | 1.17% | 178 | 10.56% | 100 | -2.91% |
| Mar 31, 2025 | 319 | -4.20% | 88,821,804 | 1.51% | 92 | 1.10% | 161 | -5.29% | 104 | -4.59% |
| Dec 31, 2024 | 195 | -38.87% | 51,382,783 | -40.24% | 53 | 0.66% | 96 | -43.86% | 71 | -24.47% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard US Total Market Shares ETF | 2.81M | 3.04% | 92.60K |
| Vanguard Total Stock Mkt Idx Inv | 2.90M | 3.00% | 12.02K |
| State Street® SPDR® S&P® Biotech ETF | 2.71M | 2.80% | -14.49K |
| Sands Capital Select Growth TE Inst EQ | 2.09M | 2.16% | -223.04K |
| Vanguard Small Cap Index | 2.08M | 2.15% | -3.02K |
| JPMorgan Mid Cap Growth I | 1.59M | 1.65% | -10.19K |
| JPM US Mid Cap Growth-Composite | 1.59M | 1.65% | -37.19K |
| Vanguard Explorer Inv | 1.53M | 1.58% | 240.90K |
| Hartford MidCap Y | 1.28M | 1.39% | -24.56K |
| DWS Vermögensbildungsfonds I LD | 1.18M | 1.22% | 4.00 |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 10, 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | $79.53K |
| Mar 06, 2026 | Parschauer Karah Herdman | EVP and Chief Legal Officer | Sell | $128.79K |
| Mar 02, 2026 | Pinion John Richard | See Remarks | Sell | $228.66K |
| Mar 02, 2026 | Harris Erik | EVP & Chief Commercial Officer | Sell | $240.29K |
| Mar 02, 2026 | KAKKIS EMIL D | President & CEO | Sell | $1.24M |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 13 |
| 2025 Q4 | - | 3 |
| 2025 Q3 | - | 3 |
| 2025 Q2 | - | 3 |
| 2025 Q1 | - | 11 |
RARE Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools